LEXXNasdaqPharmaceutical PreparationsFiscal year ends August 31
Lexaria Bioscience Corp.
Financials through Q3 FY2026, quarter ended May 31, 2026Last filing: 10-Q on Jul 13, 2026
$2.60−0.26 (-9.09%)
Close on Oct 19, 2026
- Market cap
- $64.50M
- P/E (TTM)
- –
- Dividend yield
- –
Lexaria Bioscience Corp. revenue by segment
By business segment
| Revenue | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IP Licensing [Member] | $0 | $20.00K | $0 | $174.00K | $174.00K | $174.00K | $174.00K | $84.00K | $84.00K | $145.00K | $144.99K | $41.87K | – | -100.0% |
| Corporate | – | – | – | – | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | – | – |
| Consolidated [Member] | – | – | – | – | $174.00K | – | – | – | $84.00K | – | – | – | – | – |
By product or service
| Revenue | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IP Licensing [Member] | $0 | $20.00K | $0 | $174.00K | $174.00K | $174.00K | $174.00K | $84.00K | $84.00K | – | – | – | – | -100.0% |
| B2B [Member] | $0 | $0 | $0 | $0 | $0 | $0 | $9.92K | $0 | $0 | – | – | – | – | – |
| R&D [Member] | – | – | – | – | $0 | $0 | $0 | $0 | $0 | $0 | $900 | – | – | – |
| Other [Member] | – | – | – | $0 | $0 | – | – | $0 | $0 | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Lexaria Bioscience's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.